Traws Pharma
TRAW
19 hedge funds and large institutions have $1.87M invested in Traws Pharma in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
11.73% less ownership
Funds ownership: 34.44% → 22.71% (-12%)
53% less capital invested
Capital invested by funds: $3.98M → $1.87M (-$2.11M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$27.4K |
| 2 |
Two Sigma Investments
New York
|
+$25.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.74K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$163 |
| 5 |
Citigroup
New York
|
+$96 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$970K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$76.6K |
| 3 |
VPC
Vestal Point Capital
New York
|
-$40.1K |
| 4 |
Millennium Management
New York
|
-$23.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18K |
TRAW Hedge Fund Activity: Q2 2025 in Review
19 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2025, worth a combined $1.87M — down 53% from $3.98M a quarter earlier.
Fund positioning in TRAW was balanced in Q2 2025: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $27.4K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $970K sold.
- 19 institutional investors held Traws Pharma (TRAW) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $1.87M of Traws Pharma stock for Q2 2025, down 53% quarter-over-quarter.
- 4 funds opened new Traws Pharma positions in Q2 2025 and 4 closed out, a net change of 0 holders.
- The largest Traws Pharma buyer in Q2 2025 was Two Sigma Securities, an estimated $27.4K added.
- The largest Traws Pharma seller in Q2 2025 was Perceptive Advisors, an estimated $970K sold.
Based on aggregated 13F filings for Q2 2025.